20/20 Biolabs Common Stock Receivables

20/20 Biolabs Common Stock posts a receivables of $200K as of March 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Receivables is one piece of 20/20 Biolabs Common Stock's financial statement story. At $200K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AIDX's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; 20/20 Biolabs Common Stock's other metric pages and overview cover the third.